New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Kevin Byrnes Biography and Net Worth

Director of Medifast

Kevin G. Byrnes is a businessperson who has been at the helm of 5 different companies is on the board of Medifast, Inc. and Associated Catholic Charities, Inc. and Chairman for Stevenson University.

In the past Mr. Byrnes was Chairman at Bay National Corp., Chairman of Bay Bank, FSB (Lutherville, Maryland), President & Chief Operating Officer for Provident Bankshares Corp. and President & Chief Operating Officer at Provident Bank of Maryland.

Kevin G. Byrnes received an undergraduate degree from Pace University.

What is Kevin G. Byrnes' net worth?: The estimated net worth of Kevin G. Byrnes is at least $147,913.56 as of August 20th, 2021. Mr. Byrnes owns 8,154 shares of Medifast stock worth more than $147,914 as of November 17th. This net worth approximation does not reflect any other investments that Mr. Byrnes may own. Learn More about Kevin G. Byrnes' net worth.
How do I contact Kevin G. Byrnes?: The corporate mailing address for Mr. Byrnes and other Medifast executives is 100 International Drive, Baltimore MD, 21202. Medifast can also be reached via phone at (410) 581-8042 and via email at [email protected]. Learn More on Kevin G. Byrnes' contact information.
Has Kevin G. Byrnes been buying or selling shares of Medifast?: Kevin G. Byrnes has not been actively trading shares of Medifast during the last quarter. Most recently, Kevin G. Byrnes sold 673 shares of the business's stock in a transaction on Friday, August 20th. The shares were sold at an average price of $221.99, for a transaction totalling $149,399.27. Following the completion of the sale, the director now directly owns 8,154 shares of the company's stock, valued at $1,810,106.46. Learn More on Kevin G. Byrnes' trading history.
Who are Medifast's active insiders?: Medifast's insider roster includes Jeffrey Brown (Director), Kevin Byrnes (Director), Daniel Chard (CEO), and Constance Hallquist (Director). Learn More on Medifast's active insiders.
Are insiders buying or selling shares of Medifast?: During the last year, insiders at the specialty retailer sold shares 1 times. They sold a total of 4,053 shares worth more than $159,850.32. The most recent insider tranaction occured on March, 8th when Director Scott Schlackman sold 4,053 shares worth more than $159,850.32. Insiders at Medifast own 2.5% of the company. Learn More about insider trades at Medifast.
Information on this page was last updated on 3/8/2024.

Kevin G. Byrnes Insider Trading History at Medifast

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/20/2021	Sell	673	$221.99	$149,399.27	8,154

Kevin G. Byrnes Buying and Selling Activity at Medifast

Medifast Company Overview

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Today's Range

Now: $18.14

$18.08

$18.59

50 Day Range

MA: $18.56

$17.31

$20.44

2 Week Range

Now: $18.14

$17.07

$76.42

Volume

145,705 shs

Average Volume

191,551 shs

Market Capitalization

$198.45 million

P/E Ratio

27.48

Dividend Yield

N/A

Beta

1.13